James Longstreth

ORCID: 0000-0001-6642-6395
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Wnt/β-catenin signaling in development and cancer
  • Glycogen Storage Diseases and Myoclonus
  • Carbohydrate Chemistry and Synthesis
  • Hormonal and reproductive studies
  • Drug Transport and Resistance Mechanisms
  • Antibiotics Pharmacokinetics and Efficacy
  • Pharmacological Effects and Assays
  • Pharmacology and Obesity Treatment
  • Herpesvirus Infections and Treatments
  • Antibiotic Resistance in Bacteria
  • Biochemical and Molecular Research
  • Epilepsy research and treatment
  • HIV/AIDS drug development and treatment
  • Anesthesia and Sedative Agents
  • Pharmaceutical studies and practices
  • Treatment of Major Depression
  • Drug Solubulity and Delivery Systems
  • Metabolism and Genetic Disorders
  • Ovarian function and disorders
  • Clostridium difficile and Clostridium perfringens research
  • Hepatitis C virus research
  • Analytical Chemistry and Chromatography
  • Cytomegalovirus and herpesvirus research
  • Cardiac electrophysiology and arrhythmias
  • Pharmacological Effects and Toxicity Studies

University of Saint Mary of the Lake
2001-2020

Clarus Therapeutics (United States)
2012

Vancouver Clinic
2005

University of Chicago Medical Center
2002

Rhode Island Hospital
1993

University of California, San Diego
1987

Cornell University
1971-1987

Johns Hopkins University
1975-1983

Johns Hopkins Medicine
1976-1983

University of Baltimore
1977-1982

10.1002/jps.2600600803 article EN Journal of Pharmaceutical Sciences 1971-08-01

Two hundred fifty-eight patients with suspected sepsis were treated tobramycin or gentamicin in a prospective, randomized, double-blind trial. One forty-six received nine more doses, had serial determinations of serum creatinine, and evaluated for nephrotoxicity; 91 able to cooperate audiometry auditory toxicity. Auditory toxicity developed five 47 (10 per cent) given 44 (11 tobramycin. Nephrotoxicity 19 72 (26 74 (12 (P less than 0.025). The severity the nephrotoxicity was not different;...

10.1056/nejm198005153022002 article EN New England Journal of Medicine 1980-05-15

Transdermal delivery of testosterone (T) represents an effective alternative to injectable androgens. T patches normalize serum levels and reverse the symptoms androgen deficiency in hypogonadal men. However, acceptance closed system has been limited by skin irritation and/or lack adherence. gels have proposed as modes that minimize these problems. In this study we examined pharmacokinetic profiles after 1, 30, 90, 180 days daily application 2 doses gel (50 100 mg 5 10 g gel, delivering...

10.1210/jcem.85.12.7045 article EN The Journal of Clinical Endocrinology & Metabolism 2000-12-01

Abstract Context A novel formulation of oral testosterone (T) undecanoate (TU) was evaluated in a phase 3 clinical trial. Objective Determine efficacy, short-term safety, and alignment new TU with current US approval standards for T replacement therapy. Design Randomized, active-controlled, open-label study. Setting Patients Academic private practice sites; enrolled patients were clinically hypogonadal men 18 to 65 years old. Methods randomized 3:1 TU, as prescribed (JATENZO®; n = 166) or...

10.1210/clinem/dgaa238 article EN cc-by The Journal of Clinical Endocrinology & Metabolism 2020-05-08

Abstract Testosterone (T) in a hydroalcoholic gel has been developed as an effective and convenient open system for transdermal delivery of the hormone to men. Because can be applied either small or large areas skin, it was important assess whether skin surface area on which determinant serum T levels. To answer this question, pharmacokinetics 1% preparation studied nine hypogonadal The subjects random order 25-mg metered dose four times at one site (left arm/shoulder) different sites right...

10.1210/jcem.85.3.6437 article EN The Journal of Clinical Endocrinology & Metabolism 2000-03-01

Background. Leflunomide (Arava), a drug widely used for treatment of rheumatoid arthritis, has very promising background in experimental transplantation. Its activity models chronic rejection, its synergy with calcineurin phosphatase inhibitors, and inhibitory effects on herpes virus replication are compelling reasons to pursue clinical evaluation We report the use this over past 3 years various situations. Methods. A retrospective review was performed 53 liver kidney transplant recipients...

10.1097/00007890-200202150-00008 article EN Transplantation 2002-02-01

The effects of probenecid on the pharmacokinetics and renal clearance acyclovir were studied in humans. Acyclovir (5 mg/kg) was given as a 1-h infusion to three volunteers with normal function both before after oral administration (1 g). kinetics well described by two-compartment open model zero-order infusion. mean concentrations at all time points 1.0 h from end following statistically higher than corresponding without administration. In absence probenecid, (248 +/- 80 ml/min per 1.73 m2)...

10.1128/aac.21.5.804 article EN Antimicrobial Agents and Chemotherapy 1982-05-01

Ribavirin is a broad-spectrum antiviral drug that has in vitro activity against human immunodeficiency virus. To determine the kinetics of ribavirin, 17 symptom-free homosexual men with lymphadenopathy were studied. Single doses 600, 1200, or 2400 mg, given orally intravenously. The plasma ribavirin concentration-time profiles well fitted by three-compartment open model. followed linear over dose range mean 1-hour postinfusion concentrations after intravenous and 8.0, 19.7, 37.1 μmol/L,...

10.1038/clpt.1987.70 article EN Clinical Pharmacology & Therapeutics 1987-05-01

The pharmacokinetics and tolerance of acyclovir administered intravenously in single doses 2.5, 5.0, 10.0, 15.0 mg/kg were studied 13 volunteers. mean concentrations (+/- standard deviations) at the end infusion as measured by radioimmunoassay 4.52 +/0 0.31, 8.28 +/- 2.61, 14.6 2.30, 22.7 10.4 microgram/ml, respectively. Drug elimination during after was well described a two-compartment open model. terminal plasma half-life for each groups 2.85, 2.80, 3.30, 2.38 h, Within 72 h start...

10.1128/aac.21.3.393 article EN Antimicrobial Agents and Chemotherapy 1982-03-01

SYN-004 (ribaxamase) is a β-lactamase designed to be orally administered concurrently with intravenous β-lactam antibiotics, including most penicillins and cephalosporins. Ribaxamase's anticipated mechanism of action degrade excess antibiotic that excreted into the small intestine. This enzymatic inactivation expected protect gut microbiome from disruption thus prevent undesirable side effects, secondary infections such as Clostridium difficile infections, well other antibiotic-associated...

10.1128/aac.02197-16 article EN cc-by Antimicrobial Agents and Chemotherapy 2017-01-05

Enterally-administered nimodipine is the only approved drug formulation available in United States for treatment of patients with aneurysmal subarachnoid hemorrhage. Intravenous other countries but it contains a high concentration ethanol that irritating to vasculature, can alter effects medications, impair neurological assessments and potentially harmful liver. We developed sterile aqueous solution solubilized polysorbate 80 micelles (GTX-104) circumvents these problems. GTX-104 has been...

10.1101/2025.04.06.25325334 preprint EN cc-by medRxiv (Cold Spring Harbor Laboratory) 2025-04-07

Acyclovir (ACV) is almost entirely eliminated by the kidneys and has a terminal plasma half-life (t½) of 2 to 3 hr in subjects with normal renal function. To determine drug's kinetics tolerance patients severe failure, six anuric on long-term hemodialysis were studied. Each received 1-hr infusion 2.5 mg/kg IV ACV. The are well described two-compartment open model. ACV t½ total body clearance 19.5 ± 5.9 (x̄ SD) 28.6 9.5 ml / min 1.73 m2. Peak (end infusion) 8- 24-hr concentrations 37.5 23.3,...

10.1038/clpt.1982.83 article EN Clinical Pharmacology & Therapeutics 1982-05-01

Many hypogonadal men prefer oral testosterone (T) treatment. Oral T undecanoate (TU) is available in many countries, but not the United States. We aimed to assess pharmacokinetics of TU a new self-emulsifying drug delivery system formulation. Pharmacokinetics studies were conducted 3 parts: 12 enrolled 2 centers for 1-day dosing study; 29 participants from 7-day and 15 1 center 28-day study. Serial blood samples serum sex hormone measurements by liquid chromatography-tandem mass spectrometry...

10.2164/jandrol.111.013169 article EN Andrology 2012-01-26

A model system, discussed and developed in detail previous publications, was used to predict the distribution of 3′,5′-tritiated methotrexate (MTX) several mammalian species. Data from experimental studies showed predictive capabilities this when its parameters are chosen account for physiological differences among Some awareness critical factors explaining complex plasma concentration history MTX resulted during development model. Important aspects were: a) liver uptake biliary secretion;...

10.1093/jnci/46.4.775 article EN JNCI Journal of the National Cancer Institute 1971-04-01

Stereoselective verapamil disposition and dynamics were evaluated after racemic administration of single i.v. doses, simulated steady-state intravenous infusions, chronic (1 week) oral immediate-release tablets (120 mg three times daily) sustained-release (240 once to 15 young (mean +/- S.E.M. age 22 1 year) older (69 healthy male volunteers. After doses S-verapamil clearance (young, 102 6 vs. older, 77 l/hr; P < .01) R-verapamil 61 3 45 similarly decreased. Electrocardiographic P-R...

10.1016/s0022-3565(25)38406-5 article EN Journal of Pharmacology and Experimental Therapeutics 1993-08-01

To evaluate the influence of food, time dosing, and body position on steady‐state pharmacokinetics an osmotically controlled formulation verapamil (COER‐verapamil), each 29 healthy men received one tablet a day at specified times in open‐label, multiple‐dose, four‐period, crossover study. The tablets were administered randomized, balanced, design: 240 mg 8:00 AM empty stomach, subjects remaining ambulatory;240 supine for 8 hours; 10:00 PM with standardized meal, hours. Plasma concentrations...

10.1002/j.1552-4604.1995.tb04031.x article EN The Journal of Clinical Pharmacology 1995-11-01

Multidose netilmicin and gentamicin kinetics were studied in 20 healthy subjects who received 1.7 mg/kg (n = 10) or as a 20-min infusion every 8 hr for 10 days (28 doses) during randomized, double-blind comparative trial designed to study adverse effects of gentamicin. the same order with exception terminal plasma t½ (94 156 hr) volume distribution at steady state (450 1072 ml/kg). Mean peak concentrations slightly lower than Percentage dose eliminated urine did not differ two...

10.1038/clpt.1983.227 article EN Clinical Pharmacology & Therapeutics 1983-11-01

Abstract: This study investigates the effect of dietary fat on testosterone (T) pharmacokinetics in hypogonadal men following administration a self‐emulsifying capsule formulation oral T undecanoate (TU). In an open‐label, 2‐center, 5‐way crossover study, single dose TU containing 300‐mg equivalents (maximum anticipated human per administration) wasadministeredto16hypogonadal menwith washout period at least 5 days between doses. All participants were randomized to receive capsules fasting or...

10.2164/jandrol.112.017020 article EN Andrology 2012-11-12

Abstract Purpose: The safety, pharmacokinetics, and efficacy of elraglusib, a glycogen synthase kinase-3β (GSK-3β) small-molecule inhibitor, as monotherapy or combined with chemotherapy, in patients relapsed refractory solid tumors hematologic malignancies was studied. Patients Methods: Elraglusib (intravenously twice weekly 3-week cycles) dose escalation followed by eight chemotherapy regimens (gemcitabine, doxorubicin, lomustine, carboplatin, irinotecan, gemcitabine/nab-paclitaxel,...

10.1158/1078-0432.ccr-23-1916 article EN Clinical Cancer Research 2023-11-20
Coming Soon ...